Amgen Foundation commits $2.5 million in new grants to engage 50,000 students each year in the thrill of scientific inquiry

AmgenThe Amgen Foundation has announced $2.5 million in new grants for the Amgen Biotech Experience, an innovative science education program, bringing the total committed to nearly $8 million since the program's inception in 1990. The Amgen Biotech Experience provides a real-world biotech lab experience to middle and high schools in Amgen's U.S. and United Kingdom (U.K.) communities and will engage more than 50,000 students this year. Education Development Center, Inc. (EDC), a global nonprofit organization that creates learning opportunities around the world, has also been named Program Office to oversee the program's implementation and facilitate its continued development.

Cutbacks in educational funding have led to limited resources for hands-on scientific experiences in many communities, and the National Academies' National Research Council has shown a significant connection between strong lab experiences and teachers' abilities to generate student interest in science. The Amgen Biotech Experience seeks to help make this connection in secondary school classrooms by introducing students to contemporary science techniques, including a robust, hands-on curriculum, research-grade equipment and comprehensive teacher training.

"By providing cutting-edge scientific experience today, students can begin to develop capabilities to make a powerful impact on society tomorrow," said Robert A. Bradway, chairman and chief executive officer of Amgen. "The Amgen Biotech Experience, designed in collaboration with educators and Amgen scientists, provides a rigorous real-world experience that helps open students' eyes to the world of biotechnology and scientific discovery."

In 2013, the Amgen Foundation will give more than $2.5 million in grants to community colleges, universities and nonprofit organizations that lead and support the Amgen Biotech Experience in different regions across the country where Amgen has a presence, including Southern and Northern California, Colorado, Washington, Rhode Island, Massachusetts, Puerto Rico and the U.K. The program will also be introduced in Washington, D.C., in 2014.

Since 1990, the Amgen Biotech Experience has engaged more than 300,000 students in learning molecular biology using relevant curricula, tools and techniques. Teachers are given a hands-on, inquiry-based, biology curriculum, in addition to a full suite of transportable, research-grade equipment and supplies, at no cost to the participating schools. Utilizing Nobel Prize-winning discoveries to prepare a recombinant DNA molecule that carries a gene for red fluorescent protein, students follow many of the steps biotechnology researchers use to produce medicines.

"I have been using the Amgen Biotech Experience in my classroom since 2008, and it is inspiring to see how eager the students are to learn these lab techniques. Several students have even told me they want to pursue a major in biology after they finish the course," said Amy Welch, a biology teacher at Brea Olinda High School in Brea, Calif. "As a teacher, my knowledge of biotechnology lab techniques has increased immensely since I first implemented the program and I feel that I am providing my students with skills that make them strong scientific thinkers. Given its genuine impact, I am so thankful to the Amgen Foundation for making this program possible."

Beginning this year, EDC will apply its deep experience in designing and delivering high-quality science education programs to establishing a Program Office for the Amgen Biotech Experience. Working closely with existing sites, EDC will build on the assets of the program and implement strategies to enrich the program, including the introduction of a new strengthened curriculum for this school year.

"EDC has a 50-year history of sharing the excitement of science learning with teachers and students," said Luther Luedtke, president and chief executive officer of EDC. "We are pleased to work alongside the Amgen Foundation to continue to make science compelling in the classroom and to encourage students to take up science-related careers."

For more information, please visit www.amgenbiotechexperience.com.

The Amgen Foundation supports numerous national and international organizations that strive to strengthen STEM (science, technology, engineering, mathematics) education and inspire students to pursue careers in science. To date, the Amgen Foundation has committed more than $80 million in science education funding to nonprofit organizations throughout the U.S., Puerto Rico and Europe.

About Amgen Foundation
The Amgen Foundation seeks to advance science education, improve patient access to quality care, and strengthen the communities where Amgen staff members live and work. To date, the Foundation has donated more than $200 million in grants to nonprofit organizations throughout the United States, Puerto Rico and Europe that impact society in inspiring and innovative ways, and those that provide disaster relief efforts both domestically and internationally.

About EDC
Education Development Center, Inc. (EDC) is a global nonprofit organization with headquarters located outside Boston, Massachusetts. EDC's mission is to create learning opportunities for people around the world, empowering them to pursue healthier and more productive lives. EDC works with public-sector and private partners, harnessing the power of people and systems to improve education, health promotion and care, workforce preparation, communications technologies and civic engagement. EDC manages 250 projects in 30 countries.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]